Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
37.31
-0.62 (-1.63%)
At close: Jul 24, 2025, 4:00 PM
36.92
-0.39 (-1.05%)
After-hours: Jul 24, 2025, 6:11 PM EDT
Cytokinetics Revenue
Cytokinetics had revenue of $1.58M in the quarter ending March 31, 2025, with 89.10% growth. This brings the company's revenue in the last twelve months to $19.22M, up 412.21% year-over-year. In the year 2024, Cytokinetics had annual revenue of $18.47M with 145.34% growth.
Revenue (ttm)
$19.22M
Revenue Growth
+412.21%
P/S Ratio
225.44
Revenue / Employee
$38,590
Employees
498
Market Cap
4.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
| Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
| Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
| Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
| Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CYTK News
- 11 hours ago - Cytokinetics to Announce Second Quarter Results On August 7, 2025 - GlobeNewsWire
- 6 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 14 days ago - Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - GlobeNewsWire
- 5 weeks ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - GlobeNewsWire
- 2 months ago - Cytokinetics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation - Accesswire